{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:32:16Z","timestamp":1773779536453,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1111\/igc.0b013e3181a389e6","type":"journal-article","created":{"date-parts":[[2010,12,3]],"date-time":"2010-12-03T13:53:16Z","timestamp":1291384396000},"page":"605-610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Angiogenesis, Vasculogenesis, and Vasculogenic Mimicry in Ovarian Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Hao-Sha","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Ji","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang-Qing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/IGC.0b013e3181a389e6_bb0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1023\/A:1009222030539","article-title":"Endometrial angiogenesis","volume":"2","author":"Rogers","year":"1998","journal-title":"Angiogenesis."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0010","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1158\/0008-5472.CAN-05-4654","article-title":"Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer","volume":"66","author":"Dome","year":"2006","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0015","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am J Pathol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0140-6736(96)06071-0","article-title":"Epithelial ovarian carcinoma","volume":"349","author":"Kristensen","year":"1997","journal-title":"Lancet."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0025","first-page":"3925","article-title":"Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable","volume":"26","author":"Gadducci","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/PPO.0b013e31815a7b69","article-title":"Antiangiogenic therapy for cancer: an update","volume":"13","author":"Shojaei","year":"2007","journal-title":"Cancer J."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0035","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/ncponc1051","article-title":"Angiogenesis as a strategic target for ovarian cancer therapy","volume":"5","author":"Spannuth","year":"2008","journal-title":"Nat Clin Pract Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2006.01.030","article-title":"Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer","volume":"102","author":"Cohn","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2006.05.006","article-title":"Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer","volume":"102","author":"Monk","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0050","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ygyno.2006.05.018","article-title":"The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma","volume":"102","author":"Numnum","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0055","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/jco.2006.24.18_suppl.5019","article-title":"A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer","volume":"24","author":"Wright","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0060","first-page":"82","article-title":"Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor","volume":"14","author":"Sonmezer","year":"2004","journal-title":"Int J Gynecol Cancer."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0065","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0070","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0075","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.4161\/cc.5.16.3018","article-title":"Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch","volume":"5","author":"Naumov","year":"2006","journal-title":"Cell Cycle."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0080","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/35025215","article-title":"Vascular-specific growth factors and blood vessel formation","volume":"407","author":"Yancopoulos","year":"2000","journal-title":"Nature."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0085","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/35036374","article-title":"Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis","volume":"2","author":"Bergers","year":"2000","journal-title":"Nat Cell Biol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0090","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-04-2427","article-title":"Endogenous inhibitors of angiogenesis","volume":"65","author":"Nyberg","year":"2005","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0095","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0100","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04480","article-title":"Lymphangiogenesis in development and human disease","volume":"438","author":"Alitalo","year":"2005","journal-title":"Nature."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1054\/bjoc.2000.1228","article-title":"Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma","volume":"83","author":"Shen","year":"2000","journal-title":"Br J Cancer."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0110","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-06-3608","article-title":"Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells","volume":"67","author":"Schumacher","year":"2007","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0115","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","article-title":"Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization","volume":"153","author":"Mesiano","year":"1998","journal-title":"Am J Pathol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0120","first-page":"89","article-title":"Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer","volume":"10","author":"Yabushita","year":"2003","journal-title":"Oncol Rep."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0125","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0130","doi-asserted-by":"crossref","first-page":"10625","DOI":"10.1073\/pnas.0704213104","article-title":"Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+\/min mice","volume":"104","author":"Korsisaari","year":"2007","journal-title":"Proc Natl Acad Sci U SA."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer","volume":"3","author":"Jain","year":"2006","journal-title":"Nat Clin Pract Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0140","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0145","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0155","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/jco.2006.24.18_suppl.5018","article-title":"Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: preliminary results of a multi-center phase II trial","volume":"24","author":"Friberg","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0160","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0165","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nbt1102-1067","article-title":"Angiogenesis inhibitors suffer new setback","volume":"20","author":"Garber","year":"2002","journal-title":"Nat Biotechnol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0175","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1541-7786.36.2.1","article-title":"Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis","volume":"2","author":"Huang","year":"2004","journal-title":"Mol Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0180","first-page":"A291","article-title":"B-type natriuretic peptide enhances vasculogenesis by promoting the number and functional properties of endothelial progenitor cells","volume":"51","author":"George","year":"2008","journal-title":"J Am Coll Cardiol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0185","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nrc925","article-title":"Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?","volume":"2","author":"Rafii","year":"2002","journal-title":"Nat Rev Cancer."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0190","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1093\/emboj\/18.14.3964","article-title":"VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells","volume":"18","author":"Asahara","year":"1999","journal-title":"EMBO J."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0195","first-page":"3622","article-title":"Vasculogenesis plays a role in the growth of Ewing\u2019s sarcoma in vivo","volume":"8","author":"Bolontrade","year":"2002","journal-title":"Clin Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0200","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/ncb1288","article-title":"PDGFRA+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival","volume":"7","author":"Song","year":"2005","journal-title":"Nat Cell Biol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccr.2005.08.002","article-title":"Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors","volume":"8","author":"De Palma","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+ CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0215","doi-asserted-by":"crossref","first-page":"12493","DOI":"10.1073\/pnas.0601807103","article-title":"Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis","volume":"103","author":"Nozawa","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0220","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1097\/00002371-200411000-00208","article-title":"Tumor-infiltrating dendritic cell precursors recruited by a A-defensin contribute to vasculogenesis under the influence of VEGF-A in ovarian cancer","volume":"27","author":"Coukos","year":"2004","journal-title":"J Immunother."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0225","first-page":"620","article-title":"Peripheral blood CD34+ mononuclear cells participate in neovasculogenesis of human ovarian epithelial carcinoma","volume":"39","author":"Xu","year":"2004","journal-title":"Zhonghua Fu Chan Ke Za Zhi."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0230","first-page":"101","article-title":"Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; implications for cellular surrogate marker analysis of antiangiogenesis","volume":"7","author":"Shaked","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0235","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nbt1323","article-title":"Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells","volume":"8","author":"Shojaei","year":"2007","journal-title":"Nat Biotechnol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumor progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat Rev Cancer."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0245","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI200317929","article-title":"Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors","volume":"111","author":"Bergers","year":"2003","journal-title":"J Clin Invest."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0250","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1038\/sj.onc.1206447","article-title":"Molecular plasticity of human melanoma cells","volume":"22","author":"Hendrix","year":"2003","journal-title":"Oncogene."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0255","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/pros.10048","article-title":"Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry","volume":"50","author":"Sharma","year":"2002","journal-title":"Prostate."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0260","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4161\/cbt.316","article-title":"The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy","volume":"1","author":"Sood","year":"2002","journal-title":"Cancer Biol Ther."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0265","first-page":"1609","article-title":"Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas","volume":"25","author":"Sun","year":"2004","journal-title":"Int J Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0270","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/ijc.10423","article-title":"Vasculogenic mimicry and pseudo-comedo formation in breast cancer","volume":"99","author":"Shirakawa","year":"2002","journal-title":"Int J Cancer."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0275","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2006.12.036","article-title":"Vasculogenic mimicry: current status and future prospects","volume":"254","author":"Zhang","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0280","first-page":"1069","article-title":"Characteristics and differentiated mechanism of vascular endothelial cells-like derived from epithelial ovarian cancer cells induced by hypoxia","volume":"30","author":"Yao","year":"2007","journal-title":"Int J Oncol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0285","first-page":"665","article-title":"Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination","volume":"62","author":"Hendrix","year":"2002","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0290","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1097-0215(19990420)84:2<101::AID-IJC2>3.0.CO;2-5","article-title":"VEGF, VEGF-1, and VEGF-2, microvessel density and endothelial cell proliferation in tumors of the ovary","volume":"84","author":"Orre","year":"1999","journal-title":"Int J Cancer."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0295","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0002-9440(10)64079-5","article-title":"Molecular determinants of ovarian cancer plasticity","volume":"158","author":"Sood","year":"2001","journal-title":"Am J Pathol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0300","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/jnci\/djh267","article-title":"Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells","volume":"96","author":"Van der Schaft","year":"2004","journal-title":"J Natl Cancer Inst."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0305","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1089\/104303403322124783","article-title":"Antiangiogenic cancer therapy with microencapsulated cells","volume":"14","author":"Cirone","year":"2003","journal-title":"Hum Gene Ther."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0310","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0315","first-page":"115","article-title":"Potential role of the Slit\/Robo signal pathway in angiogenesis","volume":"11","author":"Fujiwara","year":"2006","journal-title":"Vas Med."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0320","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00018-005-5018-2","article-title":"Plexins: axon guidance and signal transduction","volume":"62","author":"Negishi","year":"2005","journal-title":"Cell Mol Life Sci."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0325","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1101\/gad.437807","article-title":"Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis","volume":"21","author":"Larrivee","year":"2007","journal-title":"Genes Dev."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0330","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.mvr.2007.06.006","article-title":"Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells","volume":"75","author":"Harrington","year":"2008","journal-title":"Microvasc Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0335","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nature05355","article-title":"Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis","volume":"444","author":"Noguera-Troise","year":"2006","journal-title":"Nature."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0340","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/nature05313","article-title":"Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis","volume":"444","author":"Ridgway","year":"2006","journal-title":"Nature."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0345","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrc2130","article-title":"The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth","volume":"7","author":"Thurston","year":"2007","journal-title":"Nat Rev Cancer."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0350","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1440-1681.2008.04880.x","article-title":"Searching for functional genetic variants in non-coding DNA","volume":"35","author":"Cobb","year":"2008","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0355","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cardiores.2004.09.032","article-title":"Transcriptional regulation of the vascular endothelial growth factor geneVa concert of activating factors","volume":"65","author":"Pages","year":"2005","journal-title":"Cardiovasc Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0360","first-page":"6531","article-title":"Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities","volume":"60","author":"Ishibashi","year":"2000","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0365","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/sj.gt.3302111","article-title":"Downregulation of TNF-alpha and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor","volume":"10","author":"Novak","year":"2003","journal-title":"Gene Ther."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0370","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/0008-5472.CAN-03-1945","article-title":"Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity","volume":"64","author":"Wei","year":"2004","journal-title":"Cancer Res."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0375","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/ng1855","article-title":"Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster","volume":"38","author":"Dews","year":"2006","journal-title":"Nat Genet."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0380","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.tips.2007.10.014","article-title":"Targeting microRNA expression to regulate angiogenesis","volume":"29","author":"Kuehbacher","year":"2008","journal-title":"Trends Pharmacol Sci."},{"key":"10.1111\/IGC.0b013e3181a389e6_bb0385","doi-asserted-by":"crossref","first-page":"R106","DOI":"10.1093\/hmg\/ddm056","article-title":"miRNAs in cancer: approaches, aetiology, diagnostics and therapy","volume":"16","author":"Blenkiron","year":"2007","journal-title":"Hum Mol Genet."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2FIGC.0b013e3181a389e6","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24039604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24039604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:08:44Z","timestamp":1753232924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24039604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S1048891X24039604"],"URL":"https:\/\/doi.org\/10.1111\/igc.0b013e3181a389e6","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiogenesis, Vasculogenesis, and Vasculogenic Mimicry in Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/IGC.0b013e3181a389e6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2009 by IGCS and ESGO","name":"copyright","label":"Copyright"}]}}